MG
SPRB

Michael Gelband’s Spruce Biosciences SPRB Stock Holding History

Michael Gelband’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Hold
22,000
– – 0.01% 1017
2026
Q1 		$1.44M Sell
22,000
-3,271
-13% -$226K 0.01% 891
2025
Q4 		$2.2M Buy
+25,271
New +$2.71M 0.02% 733
2024
Q3 		– Sell
-5,156
Closed -$200K – 2188
2024
Q2 		$200K Buy
5,156
+2,158
+72% +$116K ﹤0.01% 1396
2024
Q1 		$177K Buy
+2,998
New +$762K ﹤0.01% 1369

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Michael Gelband's SPRB Position: Q2 2026 in Review

Michael Gelband held its Spruce Biosciences (SPRB) position steady in Q2 2026 at 22,000 shares worth $1.19M. The position accounts for 0.01% of the portfolio, ranked #1017.

Michael Gelband first reported a position in SPRB in Q1 2024 and has held it in 5 quarters since. The position peaked at $2.2M in Q4 2025. 63 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Michael Gelband held 22,000 shares of Spruce Biosciences worth $1.19M as of Q2 2026.
  • Michael Gelband left its Spruce Biosciences share count unchanged in Q2 2026.
  • Spruce Biosciences made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1017 holding.
  • Michael Gelband first reported a position in Spruce Biosciences in Q1 2024 and has held it in 5 quarters since.
  • Michael Gelband's Spruce Biosciences position peaked at $2.2M in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.